<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="dict8/PMC7467230/results/search/disease/results.xml">
  <result pre="font-style : italic;} J Infect DisJ. Infect. DisjidThe Journal of" exact="Infectious" post="Diseases0022-18991537-6613Oxford University PressUS pmcid: 7467230 doi: 10.1093/infdis/jiz673jiz673 : Supplement"/>
  <result pre="Introduction: AcademicSubjects/MED00860AcademicSubjects/MED00290 Federal and State Action Needed to End the" exact="Infectious" post="Complications of Illicit Drug Use in the United States:"/>
  <result pre="HIVMA’s Advocacy Agenda SpringerSandra A1BarocasJoshua A2WurcelAlysse3NijhawanAnk4ThakararKinna56LynfieldRuth7HurleyHermione8SnowdenJessica9ThorntonAlice10del RioCarlos11on behalf of the" exact="Infectious" post="Diseases Society of America and HIV Medicine Association’s Infectious"/>
  <result pre="Advocacy Agenda SpringerSandra A1BarocasJoshua A2WurcelAlysse3NijhawanAnk4ThakararKinna56LynfieldRuth7HurleyHermione8SnowdenJessica9ThorntonAlice10del RioCarlos11on behalf of the Infectious" exact="Diseases" post="Society of America and HIV Medicine Association’s Infectious Diseases"/>
  <result pre="the Infectious Diseases Society of America and HIV Medicine Association’s" exact="Infectious" post="Diseases and Opioid Use Disorder Working Group[1], Yale School"/>
  <result pre="Infectious Diseases Society of America and HIV Medicine Association’s Infectious" exact="Diseases" post="and Opioid Use Disorder Working Group[1], Yale School of"/>
  <result pre="America and HIV Medicine Association’s Infectious Diseases and Opioid Use" exact="Disorder" post="Working Group[1], Yale School of MedicineUSA[2], Boston UniversityUSA[3], Tufts"/>
  <result pre="New Haven, CT 06510 (sandra.springer@yale.edu). ppub: 2020-10-10epub: 2020-9-9pmc-release: 2020-9-9222Suppl 5Infectious" exact="Diseases" post="and Injection Drug Use: Public Health Burden and ResponseS230S238(C)"/>
  <result pre="and human rights-based response to illicit drug use and associated" exact="infectious diseases." post="Infectious diseases and HIV physicians have an opportunity to"/>
  <result pre="rights-based response to illicit drug use and associated infectious diseases." exact="Infectious" post="diseases and HIV physicians have an opportunity to intervene,"/>
  <result pre="further dissemination. This paper reviews (1) programs most relevant to" exact="infectious diseases" post="in the 2018 SUPPORT Act; (2) opportunities offered by"/>
  <result pre="tools and improving integrated prevention and treatment services for the" exact="infectious diseases" post="and substance use disorder care continuum. By strengthening collaborations"/>
  <result pre="integrated prevention and treatment services for the infectious diseases and" exact="substance use disorder" post="care continuum. By strengthening collaborations between infectious diseases and"/>
  <result pre="prevention and treatment services for the infectious diseases and substance" exact="use disorder" post="care continuum. By strengthening collaborations between infectious diseases and"/>
  <result pre="and substance use disorder care continuum. By strengthening collaborations between" exact="infectious diseases" post="and addiction specialists, including increasing training in substance use"/>
  <result pre="between infectious diseases and addiction specialists, including increasing training in" exact="substance use disorder" post="treatment among infectious diseases and addiction specialists, we can"/>
  <result pre="infectious diseases and addiction specialists, including increasing training in substance" exact="use disorder" post="treatment among infectious diseases and addiction specialists, we can"/>
  <result pre="specialists, including increasing training in substance use disorder treatment among" exact="infectious diseases" post="and addiction specialists, we can decrease morbidity and mortality"/>
  <result pre="epidemics. injection drug use opioid epidemic medications for treatment of" exact="opioid use disorder" post="Funding National Institute on Drug Abuse10.13039/100000026 K02 DA032322 National"/>
  <result pre="injection drug use opioid epidemic medications for treatment of opioid" exact="use disorder" post="Funding National Institute on Drug Abuse10.13039/100000026 K02 DA032322 National"/>
  <result pre="As a result, the incidence of injection drug use (IDU)-related" exact="infections" post="such as human immunodeficiency virus (HIV), hepatitis C virus"/>
  <result pre="incidence of injection drug use (IDU)-related infections such as human" exact="immunodeficiency" post="virus (HIV), hepatitis C virus (HCV), hepatitis B virus"/>
  <result pre="drug use (IDU)-related infections such as human immunodeficiency virus (HIV)," exact="hepatitis C" post="virus (HCV), hepatitis B virus (HBV), and invasive bacterial"/>
  <result pre="such as human immunodeficiency virus (HIV), hepatitis C virus (HCV)," exact="hepatitis" post="B virus (HBV), and invasive bacterial and fungal infections,"/>
  <result pre="hepatitis C virus (HCV), hepatitis B virus (HBV), and invasive" exact="bacterial" post="and fungal infections, including Staphylococcus aureus bacteremia, endocarditis, and"/>
  <result pre="throughout the country [4, 10–12]. In addition to HIV, both" exact="acute" post="HCV and HBV infection incidence has mirrored the rise"/>
  <result pre="10–12]. In addition to HIV, both acute HCV and HBV" exact="infection" post="incidence has mirrored the rise in injection opioids [5,"/>
  <result pre="in injection opioids [5, 13] and hospitalizations for injection opioid-related" exact="endocarditis" post="have increased more than 12-fold in recent years [6,"/>
  <result pre="in the United States. This plan seeks to reduce new" exact="infections" post="by 75% in the next 5 years and by"/>
  <result pre="the HIV epidemic as well as HCV and other IDU-related" exact="infections" post="also requires a focus on the opioid and co-occurring"/>
  <result pre="improve patients’ outcomes and reduce the public health risk of" exact="infectious disease" post="transmission. Nevertheless, a number of barriers to care in"/>
  <result pre="patients’ outcomes and reduce the public health risk of infectious" exact="disease" post="transmission. Nevertheless, a number of barriers to care in"/>
  <result pre="in the United States as well as reduce the other" exact="infectious disease" post="health outcomes. To address these barriers we recommend expanding"/>
  <result pre="the United States as well as reduce the other infectious" exact="disease" post="health outcomes. To address these barriers we recommend expanding"/>
  <result pre="paper are members of a working group created by the" exact="Infectious" post="Diseases Society of America (IDSA) and the HIV Medicine"/>
  <result pre="are members of a working group created by the Infectious" exact="Diseases" post="Society of America (IDSA) and the HIV Medicine Association"/>
  <result pre="on the urgent need to better prevent and treat serious" exact="infections" post="linked to the opioid and stimulant epidemics and underlying"/>
  <result pre="working group developed a policy agenda reflecting issues raised by" exact="infectious diseases" post="and HIV physicians and health care professionals working at"/>
  <result pre="physicians and health care professionals working at the intersection of" exact="infectious diseases" post="and opioid use disorder (OUD) and other SUD epidemics"/>
  <result pre="care professionals working at the intersection of infectious diseases and" exact="opioid use disorder" post="(OUD) and other SUD epidemics more broadly. In this"/>
  <result pre="professionals working at the intersection of infectious diseases and opioid" exact="use disorder" post="(OUD) and other SUD epidemics more broadly. In this"/>
  <result pre="are likely to positively impact the OUD, stimulant epidemics, and" exact="infectious diseases" post="epidemics, and that have been reviewed and approved by"/>
  <result pre="HIVMA Board of Directors as a call to action for" exact="infectious diseases" post="and HIV practitioners. WHAT DOES TREATMENT FOR OUD ENTAIL"/>
  <result pre="IT MATTER TO INFECTIOUS DISEASES CLINICIANS? Medications for treatment of" exact="opioid use disorder" post="(MOUDs, which is now the preferred term to medication-assisted"/>
  <result pre="MATTER TO INFECTIOUS DISEASES CLINICIANS? Medications for treatment of opioid" exact="use disorder" post="(MOUDs, which is now the preferred term to medication-assisted"/>
  <result pre="Methadone is a full opioid agonist and buprenorphine is a" exact="partial" post="opioid agonist, while XR-NTX is an opioid antagonist. All"/>
  <result pre="transmission [14, 15]; and buprenorphine and XR-NTX also improve HIV" exact="viral" post="suppression in people living with HIV, the gold standard"/>
  <result pre="Of the 3 MOUDs, access to methadone and buprenorphine are" exact="limited" post="by regulations. Prescribing requires special training outside postgraduate programs"/>
  <result pre="leave the hospital, readmissions after OUD relapse, and, if concomitant" exact="infection" post="is present, lack of antibiotic adherence and reinfection. Ultimately,"/>
  <result pre="poor clinical outcomes, high health care costs, and excess deaths." exact="Infectious" post="disease specialists are at the frontlines in many hospitals"/>
  <result pre="clinical outcomes, high health care costs, and excess deaths. Infectious" exact="disease" post="specialists are at the frontlines in many hospitals treating"/>
  <result pre="disease specialists are at the frontlines in many hospitals treating" exact="infectious diseases" post="in people who use drugs and have an opportunity"/>
  <result pre="to heighten the response to the opioid epidemic and its" exact="infectious diseases" post="complications. On 24 October 2018, President Trump signed into"/>
  <result pre="October 2018, President Trump signed into law the Substance Use" exact="Disorder" post="Prevention that Promotes Opioid Recovery and Treatment (SUPPORT Act)."/>
  <result pre="pilot studies to identify effective care models for comanagement of" exact="infectious diseases" post="and SUD. 6. Increase funding for national and regional warmlines"/>
  <result pre="10. Develop a national surveillance system to report and track IDU-related" exact="infections" post="to predict and respond to emerging epidemics. 11. Integrate"/>
  <result pre="to the community. 15. Fund research to evaluate non-HIV/ HCV related" exact="infections" post="secondary to OUD/ SUD such as skin and soft"/>
  <result pre="the community. 15. Fund research to evaluate non-HIV/ HCV related infections" exact="secondary" post="to OUD/ SUD such as skin and soft tissue"/>
  <result pre="secondary to OUD/ SUD such as skin and soft tissue" exact="infections" post="and risk of endocarditis with a specific focus on"/>
  <result pre="such as skin and soft tissue infections and risk of" exact="endocarditis" post="with a specific focus on criminal justice involved populations."/>
  <result pre="a specific focus on criminal justice involved populations. Abbreviations: HCV," exact="hepatitis C" post="virus; HIV, human immunodeficiency virus; IDU, injection drug use;"/>
  <result pre="justice involved populations. Abbreviations: HCV, hepatitis C virus; HIV, human" exact="immunodeficiency" post="virus; IDU, injection drug use; MOUD, medication for treatment"/>
  <result pre="virus; IDU, injection drug use; MOUD, medication for treatment of" exact="opioid use disorder;" post="OUD, opioid use disorder; SSPs, syringe services program; SUD,"/>
  <result pre="IDU, injection drug use; MOUD, medication for treatment of opioid" exact="use disorder;" post="OUD, opioid use disorder; SSPs, syringe services program; SUD,"/>
  <result pre="use; MOUD, medication for treatment of opioid use disorder; OUD," exact="opioid use disorder;" post="SSPs, syringe services program; SUD, substance use disorder. IDSA"/>
  <result pre="MOUD, medication for treatment of opioid use disorder; OUD, opioid" exact="use disorder;" post="SSPs, syringe services program; SUD, substance use disorder. IDSA"/>
  <result pre="disorder; OUD, opioid use disorder; SSPs, syringe services program; SUD," exact="substance use disorder." post="IDSA and HIVMA supported the SUPPORT Act, including provisions"/>
  <result pre="OUD, opioid use disorder; SSPs, syringe services program; SUD, substance" exact="use disorder." post="IDSA and HIVMA supported the SUPPORT Act, including provisions"/>
  <result pre="and HIVMA were provisions authorizing funding for the Centers for" exact="Disease" post="Control and Prevention (CDC) to eliminate opioid related infections"/>
  <result pre="for Disease Control and Prevention (CDC) to eliminate opioid related" exact="infections" post="through improved surveillance and prevention for infections linked to"/>
  <result pre="eliminate opioid related infections through improved surveillance and prevention for" exact="infections" post="linked to IDU and funding for the Health Resources"/>
  <result pre="for fiscal year 2019 for the CDC Eliminate Opioid Related" exact="Infections" post="funding provision. The fiscal year 2020 appropriations bills were"/>
  <result pre="and included $10 million for the CDC’s Eliminate Opioid Related" exact="Infections" post="program and $12 million for the new substance use"/>
  <result pre="Opioid Related Infections program and $12 million for the new" exact="substance use disorder" post="loan forgiveness program [21]. Other legislative proposals supported by"/>
  <result pre="Related Infections program and $12 million for the new substance" exact="use disorder" post="loan forgiveness program [21]. Other legislative proposals supported by"/>
  <result pre="Resources Emergency Act modeled after the highly successful Ryan White" exact="HIV/AIDS" post="Program and that would provide funding to states to"/>
  <result pre="a significant barrier to expanding access to SSP services [25]." exact="Increased" post="state and federal funding are needed to expand SSP"/>
  <result pre="and other harm reduction services, including access to MOUD and" exact="infectious diseases" post="treatment services in order to decrease HCV, HIV, IDU-related"/>
  <result pre="34%, respectively [28]. SSPs also can facilitate vaccine uptake for" exact="hepatitis" post="A virus (HAV), HBV, influenza, and invasive pneumococcal disease,"/>
  <result pre="reluctant to seek nonemergent care for skin and soft tissue" exact="infections" post="and postpone medical evaluation until the need is more"/>
  <result pre="is more urgent. Providing care for skin and soft tissue" exact="infections" post="in a supported setting may reduce progression to serious"/>
  <result pre="infections in a supported setting may reduce progression to serious" exact="infections" post="and reduce complications like wound botulism or partial drainage"/>
  <result pre="may reduce progression to serious infections and reduce complications like" exact="wound botulism" post="or partial drainage of abscesses. Given the increased incidence"/>
  <result pre="reduce progression to serious infections and reduce complications like wound" exact="botulism" post="or partial drainage of abscesses. Given the increased incidence"/>
  <result pre="to serious infections and reduce complications like wound botulism or" exact="partial" post="drainage of abscesses. Given the increased incidence of IDU-associated"/>
  <result pre="partial drainage of abscesses. Given the increased incidence of IDU-associated" exact="infections" post="and overdose deaths [1, 2], there is a need"/>
  <result pre="documented need for these programs and their potential to reduce" exact="infectious diseases" post="[34, 35]. Additionally, drug paraphernalia laws, which prohibit possession"/>
  <result pre="who inject drugs having an adequate supply of sterile syringes." exact="Secondary" post="exchange, or the distribution of sterile syringes from 1"/>
  <result pre="the United States. Improving the Care Continuum for Individuals With" exact="Infectious" post="Diseases and Substance Use Disorders Significant work needs to"/>
  <result pre="United States. Improving the Care Continuum for Individuals With Infectious" exact="Diseases" post="and Substance Use Disorders Significant work needs to be"/>
  <result pre="Care Continuum for Individuals With Infectious Diseases and Substance Use" exact="Disorders" post="Significant work needs to be done to improve the"/>
  <result pre="be done to improve the care continuum for people with" exact="infectious diseases" post="and co-occurring SUD. The first step needs to be"/>
  <result pre="treatment programs that integrate substance use care and treatment for" exact="infectious" post="complications in order to improve outcomes are needed. Treatment"/>
  <result pre="outcomes are needed. Treatment of both the SUD and associated" exact="infections" post="(eg, HIV, HCV) can be cost-effective and is associated"/>
  <result pre="HIV, HCV) can be cost-effective and is associated with improved" exact="infection" post="and SUD outcomes [44]. Previous studies have shown that"/>
  <result pre="with either HIV or HCV who receive MOUDs have improved" exact="viral" post="suppression (HIV) [16, 17], achieve sustained virologic response/cure (HCV)"/>
  <result pre="needed to evaluate novel approaches to antimicrobial treatment for IDU-associated" exact="infections" post="such as the role of long-acting glycopeptides. Increased funding"/>
  <result pre="for IDU-associated infections such as the role of long-acting glycopeptides." exact="Increased" post="funding is necessary for other demonstration projects and pilot"/>
  <result pre="pilot studies to identify effective care models for comanagement of" exact="infectious diseases" post="and OUD as well as other SUDs. Additionally, we"/>
  <result pre="need to expand the network of providers prescribing MOUD. Most" exact="infectious diseases" post="and HIV physicians receive little to no formal training"/>
  <result pre="physician assistant schools, residency programs, and within hospitals. While all" exact="infectious diseases" post="and HIV physicians should become familiar with harm reduction"/>
  <result pre="national support for physicians to comanage OUD, SUDs, and co-occurring" exact="infectious diseases." post="Lack of confidence has been identified as a major"/>
  <result pre="to provide support on a number of clinical aspects of" exact="disease" post="management (Table 2) [44]. Increasing funding for national and"/>
  <result pre="substance use treatment. Table 2. Clinical Tools and Resources for" exact="Infectious" post="Disease and HIV Clinicians Buprenorphine practitioner locator https://www.samhsa.gov/medication-assisted-treatment/practitioner-program-data/treatment-practitioner-locator Buprenorphine"/>
  <result pre="use treatment. Table 2. Clinical Tools and Resources for Infectious" exact="Disease" post="and HIV Clinicians Buprenorphine practitioner locator https://www.samhsa.gov/medication-assisted-treatment/practitioner-program-data/treatment-practitioner-locator Buprenorphine waiver"/>
  <result pre="https://pcssnow.org State-targeted response technical assistance consortium https://opioidresponsenetwork.org/ Support for hospital" exact="opioid use disorder" post="treatment https://www.projectshout.org In addition, a reorganization of the buprenorphine"/>
  <result pre="State-targeted response technical assistance consortium https://opioidresponsenetwork.org/ Support for hospital opioid" exact="use disorder" post="treatment https://www.projectshout.org In addition, a reorganization of the buprenorphine"/>
  <result pre="management and other support services to clinics that prescribe MOUDs." exact="Increased" post="funding and reimbursement are also needed for low-barrier care"/>
  <result pre="innovative programs, which have already begun to be tested in" exact="infectious" post="diseases/OUD comanagement [50], have the potential to increase medication"/>
  <result pre="and collaborative decisions on complex patients, such as those with" exact="recurrent" post="endocarditis following valve repair. Evaluation of the impact of"/>
  <result pre="collaborative decisions on complex patients, such as those with recurrent" exact="endocarditis" post="following valve repair. Evaluation of the impact of these"/>
  <result pre="of child-bearing age and in prenatal care to prevent infant" exact="infection" post="[55–57]. Persons experiencing homelessness and unstable housing are similarly"/>
  <result pre="homelessness and unstable housing are similarly at increased risk for" exact="infections" post="associated with SUD. This is, in part, due to"/>
  <result pre="in part, due to the high prevalence of concomitant untreated" exact="mental illness" post="and SUD among these individuals and sanitation issues [58,"/>
  <result pre="our inability to implement effective management strategies for SUD and" exact="infections" post="in this vulnerable population. In addition to ensuring persons"/>
  <result pre="to ensuring persons who experience homelessness receive treatment of their" exact="infectious diseases" post="and SUD through low-barrier and street-based medicine programs, expanding"/>
  <result pre="SUD through low-barrier and street-based medicine programs, expanding access to" exact="stable" post="housing would also improve short- and long-term outcomes and"/>
  <result pre="for HCV infection, there is no national database of IDU-related" exact="infections" post="for surveillance, prevention activities, and program evaluation. This makes"/>
  <result pre="makes it difficult—if not impossible—to identify, predict, and prevent new" exact="infectious disease" post="epidemics related to substance use in the United States."/>
  <result pre="it difficult—if not impossible—to identify, predict, and prevent new infectious" exact="disease" post="epidemics related to substance use in the United States."/>
  <result pre="treatment and HIV resultant from IDU, but not toward the" exact="bacterial" post="and fungal infection complications, partly due to lack of"/>
  <result pre="HIV resultant from IDU, but not toward the bacterial and" exact="fungal infection" post="complications, partly due to lack of integrated surveillance systems"/>
  <result pre="resultant from IDU, but not toward the bacterial and fungal" exact="infection" post="complications, partly due to lack of integrated surveillance systems"/>
  <result pre="increasing National Institutes of Health funding for research into other" exact="infectious diseases" post="related to the worsening SUD epidemics in this country"/>
  <result pre="epidemics in this country are urgently needed. Addressing Substance Use" exact="Disorders" post="in Criminal Justice-Involved Individuals Over half of the criminal"/>
  <result pre="with a 10-fold higher prevalence than found in the general" exact="adult" post="population [62]. As such, employing and enforcing evidence-based treatment"/>
  <result pre="evidence-based treatment guidelines that address the overlap of SUD and" exact="infectious diseases" post="in the criminal justice system has the potential to"/>
  <result pre="care coordination, seamless referral to outpatient care for SUD and" exact="chronic" post="infections, and uninterrupted insurance coverage for CJIP. Intertwined with"/>
  <result pre="OUD leading to fatal overdose, progression of HIV, and HBV/HCV-induced" exact="liver disease" post="[66–68]. Additionally, overall infectious disease testing rates and rates"/>
  <result pre="leading to fatal overdose, progression of HIV, and HBV/HCV-induced liver" exact="disease" post="[66–68]. Additionally, overall infectious disease testing rates and rates"/>
  <result pre="progression of HIV, and HBV/HCV-induced liver disease [66–68]. Additionally, overall" exact="infectious disease" post="testing rates and rates of vaccination against HAV and"/>
  <result pre="of HIV, and HBV/HCV-induced liver disease [66–68]. Additionally, overall infectious" exact="disease" post="testing rates and rates of vaccination against HAV and"/>
  <result pre="against HAV and HBV are low [69, 70]. Integration of" exact="infectious disease" post="management with treatment for OUD in CJIP is an"/>
  <result pre="HAV and HBV are low [69, 70]. Integration of infectious" exact="disease" post="management with treatment for OUD in CJIP is an"/>
  <result pre="reducing these health inequities that will likely lead to improved" exact="infectious disease" post="outcomes and facilitates linkage to care postrelease [16, 17,"/>
  <result pre="these health inequities that will likely lead to improved infectious" exact="disease" post="outcomes and facilitates linkage to care postrelease [16, 17,"/>
  <result pre="also decreases postrelease mortality [72, 73] and increases postrelease HIV" exact="viral" post="suppression [16, 17]. Clearly, prevention and treatment for OUD"/>
  <result pre="[16, 17]. Clearly, prevention and treatment for OUD and associated" exact="infections" post="in this population can improve both individual outcomes and"/>
  <result pre="integrated into jails and prisons to improve substance use and" exact="infectious diseases" post="outcomes. In addition to testing and treatment, access to"/>
  <result pre="testing and treatment, access to harm reduction tools to prevent" exact="infection" post="needs to be prioritized in the CJIP. Harm reduction"/>
  <result pre="drug use but also associated with suboptimal postrelease management of" exact="chronic" post="conditions like liver disease [82]. Increased flexibility of Medicaid,"/>
  <result pre="also associated with suboptimal postrelease management of chronic conditions like" exact="liver disease" post="[82]. Increased flexibility of Medicaid, allowing initiation of insurance"/>
  <result pre="associated with suboptimal postrelease management of chronic conditions like liver" exact="disease" post="[82]. Increased flexibility of Medicaid, allowing initiation of insurance"/>
  <result pre="suboptimal postrelease management of chronic conditions like liver disease [82]." exact="Increased" post="flexibility of Medicaid, allowing initiation of insurance before release"/>
  <result pre="is needed to develop and evaluate strategies to manage non-HIV/HCV–related" exact="infections" post="secondary to IDU, such as skin and soft tissue"/>
  <result pre="needed to develop and evaluate strategies to manage non-HIV/HCV–related infections" exact="secondary" post="to IDU, such as skin and soft tissue infections"/>
  <result pre="infections secondary to IDU, such as skin and soft tissue" exact="infections" post="or infective endocarditis. Despite increasing frequency of endocarditis in"/>
  <result pre="to IDU, such as skin and soft tissue infections or" exact="infective endocarditis." post="Despite increasing frequency of endocarditis in people with OUD/SUD"/>
  <result pre="soft tissue infections or infective endocarditis. Despite increasing frequency of" exact="endocarditis" post="in people with OUD/SUD [7], and high rates of"/>
  <result pre="of history of incarceration in people with skin and soft-tissue" exact="infections" post="[7], there are limited data on the epidemiology of"/>
  <result pre="in people with skin and soft-tissue infections [7], there are" exact="limited" post="data on the epidemiology of disseminated bacterial and fungal"/>
  <result pre="[7], there are limited data on the epidemiology of disseminated" exact="bacterial" post="and fungal infections in CJIP. CONCLUSION Since the time"/>
  <result pre="limited data on the epidemiology of disseminated bacterial and fungal" exact="infections" post="in CJIP. CONCLUSION Since the time this manuscript was"/>
  <result pre="HCV, and other IDU-related infections. As a result, we as" exact="infectious disease" post="specialists need a paradigm shift in our clinical approach,"/>
  <result pre="and other IDU-related infections. As a result, we as infectious" exact="disease" post="specialists need a paradigm shift in our clinical approach,"/>
  <result pre="and aggressive policy changes to support that shift. Throughout history," exact="infectious diseases" post="clinicians have risen to the challenge. In 1998, Dr"/>
  <result pre="Supplement sponsorship. This supplement is sponsored by the Centers for" exact="Disease" post="Control and Prevention. Potential conflict of interests. S. A."/>
  <result pre="submitted work. R. L. reports royalties for a book on" exact="Infectious" post="Disease Surveillance donated to Minnesota Department of Health. All"/>
  <result pre="work. R. L. reports royalties for a book on Infectious" exact="Disease" post="Surveillance donated to Minnesota Department of Health. All other"/>
  <result pre="65:1445–52.28033313 2.RonanMV, HerzigSJHospitalizations related to opioid abuse/dependence and associated serious" exact="infections" post="increased sharply, 2002-12. Health Aff (Millwood)2016; 35:832–7.27140989 3.RuhmCJNonopioid overdose"/>
  <result pre="(Millwood)2019; 38:1216–24.31260365 4.ConradC, BradleyHM, BrozD, et al.; collab: Centers for" exact="Disease" post="Control and Prevention (CDC)Community outbreak of HIV infection linked"/>
  <result pre="collab: Centers for Disease Control and Prevention (CDC)Community outbreak of" exact="HIV infection" post="linked to injection drug use of oxymorphone–Indiana, 2015. MMWR"/>
  <result pre="Centers for Disease Control and Prevention (CDC)Community outbreak of HIV" exact="infection" post="linked to injection drug use of oxymorphone–Indiana, 2015. MMWR"/>
  <result pre="Mortal Wkly Rep2015; 64:443–4.25928470 5.ZibbellJE, AsherAK, PatelRC, et al.Increases in" exact="acute" post="hepatitis C virus infection related to a growing opioid"/>
  <result pre="Wkly Rep2015; 64:443–4.25928470 5.ZibbellJE, AsherAK, PatelRC, et al.Increases in acute" exact="hepatitis C" post="virus infection related to a growing opioid epidemic and"/>
  <result pre="64:443–4.25928470 5.ZibbellJE, AsherAK, PatelRC, et al.Increases in acute hepatitis C" exact="virus infection" post="related to a growing opioid epidemic and associated injection"/>
  <result pre="5.ZibbellJE, AsherAK, PatelRC, et al.Increases in acute hepatitis C virus" exact="infection" post="related to a growing opioid epidemic and associated injection"/>
  <result pre="Health2018; 108:175–81.29267061 6.SchranzAJ, FleischauerA, ChuVH, WuLT, RosenDLTrends in drug use-associated" exact="infective endocarditis" post="and heart valve surgery, 2007 to 2017: a study"/>
  <result pre="108:175–81.29267061 6.SchranzAJ, FleischauerA, ChuVH, WuLT, RosenDLTrends in drug use-associated infective" exact="endocarditis" post="and heart valve surgery, 2007 to 2017: a study"/>
  <result pre="6.SchranzAJ, FleischauerA, ChuVH, WuLT, RosenDLTrends in drug use-associated infective endocarditis" exact="and heart" post="valve surgery, 2007 to 2017: a study of statewide"/>
  <result pre="FleischauerA, ChuVH, WuLT, RosenDLTrends in drug use-associated infective endocarditis and" exact="heart" post="valve surgery, 2007 to 2017: a study of statewide"/>
  <result pre="data. Ann Intern Med2018; 170:31–40.30508432 7.WurcelAG, AndersonJE, ChuiKK, et al.Increasing" exact="infectious" post="endocarditis admissions among young people who inject drugs. Open"/>
  <result pre="Ann Intern Med2018; 170:31–40.30508432 7.WurcelAG, AndersonJE, ChuiKK, et al.Increasing infectious" exact="endocarditis" post="admissions among young people who inject drugs. Open Forum"/>
  <result pre="Open Forum Infect Dis2016; 3:ofw157.27800528 8.FleischauerAT, RuhlL, RheaS, BarnesEHospitalizations for" exact="endocarditis" post="and associated health care costs among persons with diagnosed"/>
  <result pre="Rep2017; 66:569–73.28594786 9.JacksonKA, BohmMK, BrooksJT, et al.Invasive methicillin-resistant Staphylococcus aureus" exact="infections" post="among persons who inject drugs—six sites, 2005–2016. MMWR Morb"/>
  <result pre="Wkly Rep2019; 68:253–4.30870405 11.GoldenMR, LechtenbergR, GlickSN, et al.Outbreak of human" exact="immunodeficiency" post="virus infection among heterosexual persons who are living homeless"/>
  <result pre="Rep2019; 68:253–4.30870405 11.GoldenMR, LechtenbergR, GlickSN, et al.Outbreak of human immunodeficiency" exact="virus infection" post="among heterosexual persons who are living homeless and inject"/>
  <result pre="68:253–4.30870405 11.GoldenMR, LechtenbergR, GlickSN, et al.Outbreak of human immunodeficiency virus" exact="infection" post="among heterosexual persons who are living homeless and inject"/>
  <result pre="Rep2019; 68:344–9.30998671 12.EvansME, LabudaSM, HoganV, et al.Notes from the field:" exact="HIV infection" post="investigation in a rural area—West Virginia, 2017. MMWR Morb"/>
  <result pre="68:344–9.30998671 12.EvansME, LabudaSM, HoganV, et al.Notes from the field: HIV" exact="infection" post="investigation in a rural area—West Virginia, 2017. MMWR Morb"/>
  <result pre="Mortal Wkly Rep2017; 67:257–8. 13.HarrisAM, IqbalK, SchillieS, et al.Increases in" exact="acute" post="hepatitis B virus infections—Kentucky, Tennessee, and West Virginia, 2006–2013."/>
  <result pre="Wkly Rep2017; 67:257–8. 13.HarrisAM, IqbalK, SchillieS, et al.Increases in acute" exact="hepatitis" post="B virus infections—Kentucky, Tennessee, and West Virginia, 2006–2013. MMWR"/>
  <result pre="AliROral substitution treatment of injecting opioid users for prevention of" exact="HIV infection." post="Cochrane Database Syst Rev2011; (8):CD004145. 16.SpringerSA, QiuJ, Saber-TehraniAS, AlticeFLRetention"/>
  <result pre="AlticeFLRetention on buprenorphine is associated with high levels of maximal" exact="viral" post="suppression among HIV-infected opioid dependent released prisoners. PLoS One2012;"/>
  <result pre="One2012; 7:e38335.22719814 17.SpringerSA, Di PaolaA, AzarMM, et al.Extended-release naltrexone improves" exact="viral" post="suppression among incarcerated persons living with HIV with opioid"/>
  <result pre="Sciences, Engineering, and Medicine. Integrating responses at the intersection of" exact="opioid use disorder" post="and infectious disease epidemics: proceedings of a workshop. Washington,"/>
  <result pre="Engineering, and Medicine. Integrating responses at the intersection of opioid" exact="use disorder" post="and infectious disease epidemics: proceedings of a workshop. Washington,"/>
  <result pre="Integrating responses at the intersection of opioid use disorder and" exact="infectious disease" post="epidemics: proceedings of a workshop. Washington, DC: National Academies"/>
  <result pre="responses at the intersection of opioid use disorder and infectious" exact="disease" post="epidemics: proceedings of a workshop. Washington, DC: National Academies"/>
  <result pre="2018. 27.SpringerSA, KorthuisPT, Del RioCintegrating treatment at the intersection of" exact="opioid use disorder" post="and infectious disease epidemics in medical settings: a call"/>
  <result pre="27.SpringerSA, KorthuisPT, Del RioCintegrating treatment at the intersection of opioid" exact="use disorder" post="and infectious disease epidemics in medical settings: a call"/>
  <result pre="RioCintegrating treatment at the intersection of opioid use disorder and" exact="infectious disease" post="epidemics in medical settings: a call for action after"/>
  <result pre="treatment at the intersection of opioid use disorder and infectious" exact="disease" post="epidemics in medical settings: a call for action after"/>
  <result pre="and meta-analysis. Addiction2018; 113:545–63.28891267 29.PeakCM, StousSS, HealyJM, et al.Homelessness and" exact="hepatitis" post="A—San Diego County, 2016–2018 [published online ahead of print"/>
  <result pre="and safety of people who inject drugs during transition from" exact="acute" post="to outpatient care: narrative review with clinical checklist. Postgrad"/>
  <result pre="35.MacArthurGJ, van VelzenE, PalmateerN, et al.Interventions to prevent HIV and" exact="hepatitis C" post="in people who inject drugs: a review of reviews"/>
  <result pre="60:177–97.29990675 42.SalonerB, LandisR, SteinBD, BarryCLThe Affordable Care Act in the" exact="heart" post="of the opioid crisis: evidence from West Virginia. Health"/>
  <result pre="enrollment in Affordable Care Act qualified health plans’ association with" exact="viral" post="suppression [published online ahead of print 18 November 2019]."/>
  <result pre="DurkinMJAddiction medicine consultations reduce readmission rates for patients with serious" exact="infections" post="from opioid use disorder. Clin Infect Dis2019; 68:1935–7.30357363 45.AkiyamaMJ,"/>
  <result pre="consultations reduce readmission rates for patients with serious infections from" exact="opioid use disorder." post="Clin Infect Dis2019; 68:1935–7.30357363 45.AkiyamaMJ, NortonBL, ArnstenJH, AgyemangL, HeoM,"/>
  <result pre="reduce readmission rates for patients with serious infections from opioid" exact="use disorder." post="Clin Infect Dis2019; 68:1935–7.30357363 45.AkiyamaMJ, NortonBL, ArnstenJH, AgyemangL, HeoM,"/>
  <result pre="Dis2019; 68:1935–7.30357363 45.AkiyamaMJ, NortonBL, ArnstenJH, AgyemangL, HeoM, LitwinAHIntensive models of" exact="hepatitis C" post="care for people who inject drugs receiving opioid agonist"/>
  <result pre="trial. Ann Intern Med2019; 170:594–603.30959528 46.AkiyamaM, LipseyD, MoonseongH, et al.Low" exact="hepatitis" post="reinfection following direct acting antiviral therapy among people who"/>
  <result pre="WalshSL, ThorntonAC, NuzzoPA, LofwallMROutpatient parenteral antimicrobial therapy plus buprenorphine for" exact="opioid use disorder" post="and severe injection-related infections [published online ahead of print"/>
  <result pre="ThorntonAC, NuzzoPA, LofwallMROutpatient parenteral antimicrobial therapy plus buprenorphine for opioid" exact="use disorder" post="and severe injection-related infections [published online ahead of print"/>
  <result pre="therapy plus buprenorphine for opioid use disorder and severe injection-related" exact="infections" post="[published online ahead of print 26 July 2019]. Clin"/>
  <result pre="50.TalalAH, AndrewsP, McleodA, et al.Integrated, co-located, telemedicine-based treatment approaches for" exact="hepatitis C" post="virus management in opioid use disorder patients on methadone."/>
  <result pre="co-located, telemedicine-based treatment approaches for hepatitis C virus management in" exact="opioid use disorder" post="patients on methadone. Clin Infect Dis2019; 69:323–31.30329042 51.KroelingerCD, RiceME,"/>
  <result pre="telemedicine-based treatment approaches for hepatitis C virus management in opioid" exact="use disorder" post="patients on methadone. Clin Infect Dis2019; 69:323–31.30329042 51.KroelingerCD, RiceME,"/>
  <result pre="Dis2019; 69:323–31.30329042 51.KroelingerCD, RiceME, CoxS, et al.State strategies to address" exact="opioid use disorder" post="among pregnant and postpartum women and infants prenatally exposed"/>
  <result pre="69:323–31.30329042 51.KroelingerCD, RiceME, CoxS, et al.State strategies to address opioid" exact="use disorder" post="among pregnant and postpartum women and infants prenatally exposed"/>
  <result pre="al.State strategies to address opioid use disorder among pregnant and" exact="postpartum" post="women and infants prenatally exposed to substances, including infants"/>
  <result pre="women and infants prenatally exposed to substances, including infants with" exact="neonatal abstinence syndrome." post="MMWR Morb Mortal Wkly Rep2019; 68:777–83.31513558 52.collab: American College"/>
  <result pre="and infants prenatally exposed to substances, including infants with neonatal" exact="abstinence syndrome." post="MMWR Morb Mortal Wkly Rep2019; 68:777–83.31513558 52.collab: American College"/>
  <result pre="neonatal abstinence syndrome. MMWR Morb Mortal Wkly Rep2019; 68:777–83.31513558 52.collab:" exact="American" post="College of Obstetricians and Gynecologists. Routine tests during pregnancy."/>
  <result pre="2019. 53.collab: US Preventive Services Task Force. Draft recommendation statement" exact="hepatitis C" post="virus infection in adolescents and adults: screening. Rockville, MD:"/>
  <result pre="US Preventive Services Task Force. Draft recommendation statement hepatitis C" exact="virus infection" post="in adolescents and adults: screening. Rockville, MD: USPSTF, 2019."/>
  <result pre="Preventive Services Task Force. Draft recommendation statement hepatitis C virus" exact="infection" post="in adolescents and adults: screening. Rockville, MD: USPSTF, 2019."/>
  <result pre="Rockville, MD: USPSTF, 2019. 54.ZibbellJE, AsherAK, PatelRC, et al.Increases in" exact="acute" post="hepatitis C virus infection related to a growing opioid"/>
  <result pre="MD: USPSTF, 2019. 54.ZibbellJE, AsherAK, PatelRC, et al.Increases in acute" exact="hepatitis C" post="virus infection related to a growing opioid epidemic and"/>
  <result pre="2019. 54.ZibbellJE, AsherAK, PatelRC, et al.Increases in acute hepatitis C" exact="virus infection" post="related to a growing opioid epidemic and associated injection"/>
  <result pre="54.ZibbellJE, AsherAK, PatelRC, et al.Increases in acute hepatitis C virus" exact="infection" post="related to a growing opioid epidemic and associated injection"/>
  <result pre="Public Health2018; 108:175–81.29267061 55.LyKN, JilesRB, TeshaleEH, FosterMA, PesanoRL, HolmbergSDHepatitis C" exact="virus infection" post="among reproductive-aged women and children in the United States,"/>
  <result pre="Health2018; 108:175–81.29267061 55.LyKN, JilesRB, TeshaleEH, FosterMA, PesanoRL, HolmbergSDHepatitis C virus" exact="infection" post="among reproductive-aged women and children in the United States,"/>
  <result pre="56.CottrellEB, ChouR, WassonN, RahmanB, GuiseJMReducing risk for mother-to-infant transmission of" exact="hepatitis C" post="virus: a systematic review for the U.S. Preventive Services"/>
  <result pre="38:1289–97. 59.BarocasJA, BeiserM, LeónC, GaetaJM, O’ConnellJJ, LinasBPExperience and outcomes of" exact="hepatitis C" post="treatment in a cohort of homeless and marginally housed"/>
  <result pre="72:129–37.30962036 61.BangsbergDR, HechtFM, CharleboisED, et al.Adherence to protease inhibitors, HIV-1" exact="viral" post="load, and development of drug resistance in an indigent"/>
  <result pre="of Justice, 2017. 63.HennesseyKA, KimAA, GriffinV, CollinsNT, WeinbaumCM, SabinKPrevalence of" exact="infection" post="with hepatitis B and C viruses and co-infection with"/>
  <result pre="2017. 63.HennesseyKA, KimAA, GriffinV, CollinsNT, WeinbaumCM, SabinKPrevalence of infection with" exact="hepatitis" post="B and C viruses and co-infection with HIV in"/>
  <result pre="and co-infection with HIV in three jails: a case for" exact="viral hepatitis" post="prevention in jails in the United States. J Urban"/>
  <result pre="co-infection with HIV in three jails: a case for viral" exact="hepatitis" post="prevention in jails in the United States. J Urban"/>
  <result pre="States. J Urban Health2009; 86:93–105. 64.ZallerN, Brinkley-RubinsteinLIncarceration, drug use, and" exact="infectious" post="diseases: a syndemic still not addressed. Lancet Infect Dis2018;"/>
  <result pre="Public Health Rep2001; 116:203–9. 71.AkiyamaMJ, ColumbusD, MacDonaldR, et al.Linkage to" exact="hepatitis C" post="care after incarceration in jail: a prospective, single arm"/>
  <result pre="pre-exposure prophylaxis for people involved in criminal justice systems. Curr" exact="HIV/AIDS" post="Rep2018; 15:93–5.29516265 77.SanderG, Shirley-BeavanS, StoneKThe global state of harm"/>
  <result pre="Infect Dis doi: 10.1093/cid/ciz383. 79.HeT, LiK, RobertsMS, et al.Prevention of" exact="hepatitis C" post="by screening and treatment in U.S. prisons. Ann Intern"/>
  <result pre="BrockmannBW, VohrF, SpauldingA, MontagueBTA budget impact analysis of newly available" exact="hepatitis C" post="therapeutics and the financial burden on a state correctional"/>
 </snippets>
</snippetsTree>
